Interactions between Copper gluconate and Veltassa
1 drug interaction and 8 additional warnings found for the following 2 drugs:
- copper gluconate
- Veltassa (patiromer)
Drug interactions
Moderate drug interactions
Moderate:
copper gluconate patiromer
Applies to: copper gluconate and Veltassa (patiromer)
Adjust dosing interval
Simultaneous administration of cation-donating preparations may reduce the potassium exchange capability of cation-exchange resins due to binding of the cation to the resin.
Management
Patients should consider separating the times of administration of the cation-exchange resin and any cation-donating preparation (e.g., mineral supplements; antacids; products containing antacids such as didanosine buffered tablets or pediatric oral solution) by several hours if possible.
References (2)
- (2001) "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals
- (2002) "Product Information. Resonium Calcium (calcium polystyrene sulfonate)." Sanofi-Synthelabo Canada Inc
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
patiromer Food/Lifestyle
Applies to: Veltassa (patiromer)
Adjust dosing interval
Patiromer can bind to some orally administered drugs, which may decrease their gastrointestinal absorption and reduce their effectiveness. According to the manufacturer, out of 28 drugs that were tested in in vitro binding studies, 14 did not show an interaction with patiromer (acetylsalicylic acid, allopurinol, amoxicillin, apixaban, atorvastatin, cephalexin, digoxin, glipizide, lisinopril, phenytoin, riboflavin, rivaroxaban, spironolactone, and valsartan). Twelve of the 14 drugs that did show an in vitro interaction were subsequently tested in in vivo studies with healthy volunteers, which revealed no changes in systemic exposure when coadministered with patiromer (amlodipine, cinacalcet, clopidogrel, furosemide, lithium, metoprolol, trimethoprim, verapamil, and warfarin). Patiromer was found to decrease systemic exposure of coadministered ciprofloxacin, levothyroxine, and metformin. However, no significant interaction occurred when patiromer and these drugs were dosed 3 hours apart.
Management
Patiromer should be administered with food at least 3 hours before or 3 hours after other oral medications. Alternatives to patiromer or the other medications should be considered if adequate dosing separation is not possible. Otherwise, clinical response and/or blood levels should be monitored where possible.
References (1)
- (2015) "Product Information. Veltassa (patiromer)." Relypsa, Inc.
Disease interactions
7 potential interactions Applies to: 7 conditions, including Constipation, Diarrhea, Liver Disease, Malabsorption Syndrome, and Magnesium Imbalance.
Biliary Obstruction
Moderate:
copper gluconate
Copper gluconate has a moderate potential interaction with Biliary Obstruction.
The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.
Constipation
Major:
Veltassa
The patiromer in Veltassa has a major potential interaction with Constipation.
The use of patiromer should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, as this agent may be ineffective and may worsen gastrointestinal conditions. Therapy with patiromer should be administered cautiously in patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders.
Diarrhea
Moderate:
Veltassa
The patiromer in Veltassa has a moderate potential interaction with Diarrhea.
Patiromer binds to magnesium in the colon, which can lead to hypomagnesemia. It is recommended to monitor serum magnesium concentrations during therapy. Therapy with patiromer should be administered cautiously in patients with or predisposed to magnesium deficiency. Consider magnesium supplementation in patients who develop low serum magnesium levels.
Gastrointestinal Obstruction
Major:
Veltassa
The patiromer in Veltassa has a major potential interaction with Gastrointestinal Obstruction.
The use of patiromer should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, as this agent may be ineffective and may worsen gastrointestinal conditions. Therapy with patiromer should be administered cautiously in patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders.
Liver Disease
Moderate:
copper gluconate
Copper gluconate has a moderate potential interaction with Liver Disease.
The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.
Magnesium Imbalance
Moderate:
Veltassa
The patiromer in Veltassa has a moderate potential interaction with Magnesium Imbalance.
Patiromer binds to magnesium in the colon, which can lead to hypomagnesemia. It is recommended to monitor serum magnesium concentrations during therapy. Therapy with patiromer should be administered cautiously in patients with or predisposed to magnesium deficiency. Consider magnesium supplementation in patients who develop low serum magnesium levels.
Malabsorption Syndrome
Moderate:
copper gluconate
Copper gluconate has a moderate potential interaction with Malabsorption Syndrome.
The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.
Report options
More resources
copper gluconate
A total of 28 drugs are known to interact with copper gluconate.
- Copper gluconate is in the drug class minerals and electrolytes.
- Copper gluconate is used to treat Vitamin/Mineral Supplementation and Deficiency.
Veltassa
A total of 164 drugs are known to interact with Veltassa.
- Veltassa is in the drug class cation exchange resins.
- Veltassa is used to treat Hyperkalemia.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.